{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T08:25:14Z","timestamp":1790324714835,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"JSPS KAKENHI","award":["20791543"],"award-info":[{"award-number":["20791543"]}]},{"name":"JSPS KAKENHI","award":["22792009"],"award-info":[{"award-number":["22792009"]}]},{"name":"Saitama Medical University Research Promotion","award":["06-01"],"award-info":[{"award-number":["06-01"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.cyto.2016.03.012","type":"journal-article","created":{"date-parts":[[2016,3,19]],"date-time":"2016-03-19T07:01:37Z","timestamp":1458370897000},"page":"1-7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Zoledronic acid increases the circulating soluble RANKL level in mice, with a further increase in lymphocyte-derived soluble RANKL in zoledronic acid- and glucocorticoid-treated mice stimulated with bacterial lipopolysaccharide"],"prefix":"10.1016","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1251-7448","authenticated-orcid":false,"given":"Takahiro","family":"Abe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoichiro","family":"Kokabu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Hori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumiko","family":"Shimamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoya","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8253-5540","authenticated-orcid":false,"given":"Tetsuya","family":"Yoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cyto.2016.03.012_b0005","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: mechanism of action and role in clinical practice","volume":"83","author":"Drake","year":"2008","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.cyto.2016.03.012_b0010","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.abb.2008.03.018","article-title":"Functions of RANKL\/RANK\/OPG in bone modeling and remodeling","volume":"473","author":"Boyce","year":"2008","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.cyto.2016.03.012_b0015","doi-asserted-by":"crossref","first-page":"4514","DOI":"10.1210\/jc.2007-0646","article-title":"CLINICAL review #: the role of receptor activator of nuclear factor-kappaB (RANK)\/RANK ligand\/osteoprotegerin: clinical implications","volume":"92","author":"Vega","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.cyto.2016.03.012_b0020","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1210\/er.2007-0014","article-title":"Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease","volume":"29","author":"Kearns","year":"2008","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.cyto.2016.03.012_b0025","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1006\/bbrc.2000.4130","article-title":"Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells","volume":"280","author":"Hofbauer","year":"2001","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.cyto.2016.03.012_b0030","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1006\/bbrc.2002.6510","article-title":"Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts","volume":"291","author":"Viereck","year":"2002","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.cyto.2016.03.012_b0035","first-page":"1720","article-title":"The effect of zoledronic acid on serum osteoprotegerin in early stage multiple myeloma","volume":"91","author":"Martini","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.cyto.2016.03.012_b0040","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.bone.2006.08.003","article-title":"Serum OPG and RANKL levels before and after intravenous bisphosphonate treatment in Paget\u2019s disease of bone","volume":"40","author":"Martini","year":"2007","journal-title":"Bone"},{"key":"10.1016\/j.cyto.2016.03.012_b0045","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1007\/s00198-005-0040-7","article-title":"Serum osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) concentrations in allogeneic stem cell transplant-recipients: a role in bone loss?","volume":"17","author":"Kananen","year":"2006","journal-title":"Osteoporosis Int."},{"key":"10.1016\/j.cyto.2016.03.012_b0050","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s00198-005-0035-4","article-title":"Changes in the RANK ligand\/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients","volume":"17","author":"Dobnig","year":"2006","journal-title":"Osteoporosis Int."},{"key":"10.1016\/j.cyto.2016.03.012_b0055","doi-asserted-by":"crossref","first-page":"6323","DOI":"10.1210\/jc.2005-0794","article-title":"Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment","volume":"90","author":"Rogers","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2012","key":"10.1016\/j.cyto.2016.03.012_b0060","first-page":"2","article-title":"Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR histomorphometry nomenclature committee","volume":"28","author":"Dempster","year":"2012","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.cyto.2016.03.012_b0065","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1172\/JCI6800","article-title":"Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin","volume":"104","author":"Plotkin","year":"1999","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cyto.2016.03.012_b0070","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1172\/JCI0214538","article-title":"Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids","volume":"109","author":"Weinstein","year":"2002","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cyto.2016.03.012_b0075","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1746-160X-6-12","article-title":"The impact of bisphosphonates on the osteoblast proliferation and collagen gene expression in vitro","volume":"6","author":"Koch","year":"2010","journal-title":"Head Face Med."},{"key":"10.1016\/j.cyto.2016.03.012_b0080","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00784-009-0312-2","article-title":"Expression profile and synthesis of different collagen types I, II, III, and V of human gingival fibroblasts, osteoblasts, and SaOS-2 cells after bisphosphonate treatment","volume":"14","author":"Simon","year":"2010","journal-title":"Clin. Oral Invest."},{"key":"10.1016\/j.cyto.2016.03.012_b0085","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/j.1601-0825.2007.01402.x","article-title":"Disparate osteogenic response of mandible and iliac crest bone marrow stromal cells to pamidronate","volume":"14","author":"Stefanik","year":"2008","journal-title":"Oral Dis."},{"key":"10.1016\/j.cyto.2016.03.012_b0090","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.tripleo.2008.03.036","article-title":"The effects of bisphosphonates on osteoblasts in vitro","volume":"106","author":"Naidu","year":"2008","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endodontol."},{"key":"10.1016\/j.cyto.2016.03.012_b0095","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/emm.2002.21","article-title":"Inhibitory action of bisphosphonates on bone resorption does not involve the regulation of RANKL and OPG expression","volume":"34","author":"Kim","year":"2002","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.cyto.2016.03.012_b0100","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1359\/jbmr.2004.19.1.147","article-title":"The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE)","volume":"19","author":"Pan","year":"2004","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.cyto.2016.03.012_b0105","doi-asserted-by":"crossref","first-page":"5441","DOI":"10.1210\/en.2003-0717","article-title":"Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption","volume":"144","author":"Nakamura","year":"2003","journal-title":"Endocrinology"},{"key":"10.1016\/j.cyto.2016.03.012_b0110","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/46303","article-title":"Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand","volume":"402","author":"Kong","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.cyto.2016.03.012_b0115","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1146\/annurev.immunol.20.100301.064753","article-title":"RANK-L and RANK: T cells, bone loss, and mammalian evolution","volume":"20","author":"Theill","year":"2002","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.cyto.2016.03.012_b0120","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1359\/jbmr.2001.16.2.328","article-title":"T cell activation induces human osteoclast formation via receptor activator of nuclear factor kappaB ligand-dependent and -independent mechanisms","volume":"16","author":"Weitzmann","year":"2001","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.cyto.2016.03.012_b0125","doi-asserted-by":"crossref","first-page":"13613","DOI":"10.1074\/jbc.274.19.13613","article-title":"Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival","volume":"274","author":"Lum","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cyto.2016.03.012_b0130","doi-asserted-by":"crossref","first-page":"192","DOI":"10.4049\/jimmunol.178.1.192","article-title":"Osteoprotegerin reduces the serum level of receptor activator of NF-kappaB ligand derived from osteoblasts","volume":"178","author":"Nakamichi","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.cyto.2016.03.012_b0135","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.bone.2003.08.013","article-title":"The nitrogen-containing bisphosphonate, zoledronic acid, increases mineralisation of human bone-derived cells in vitro","volume":"34","author":"Pan","year":"2004","journal-title":"Bone"},{"key":"10.1016\/j.cyto.2016.03.012_b0140","first-page":"2","article-title":"American association of oral and maxillofacial surgeons position paper on bisphosphonate-related osteonecrosis of the jaws\u20132009 update","volume":"67","author":"Ruggiero","year":"2009","journal-title":"J. Oral Maxillofac. Surg."},{"key":"10.1016\/j.cyto.2016.03.012_b0145","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00774-010-0162-7","volume":"28","author":"Yoneda","year":"2010","journal-title":"J. Bone Miner. Metab."}],"container-title":["Cytokine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466616300515?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466616300515?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,14]],"date-time":"2018-09-14T02:53:51Z","timestamp":1536893631000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043466616300515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":29,"alternative-id":["S1043466616300515"],"URL":"https:\/\/doi.org\/10.1016\/j.cyto.2016.03.012","relation":{},"ISSN":["1043-4666"],"issn-type":[{"value":"1043-4666","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Zoledronic acid increases the circulating soluble RANKL level in mice, with a further increase in lymphocyte-derived soluble RANKL in zoledronic acid- and glucocorticoid-treated mice stimulated with bacterial lipopolysaccharide","name":"articletitle","label":"Article Title"},{"value":"Cytokine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cyto.2016.03.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}